Brand new peer-reviewed data on Eli Lilly’s candidate tirzepatide has set the stage for a battle within the obesity market. Novo Nordisk vs Eli Lilly. Tirzepatide vs semaglutide. The US vs Denmark.
US-based industry media Fierce Pharma reports that Eli Lilly’s tirzepatide met both primary and secondary endpoints in its phase III trial Surmount 1, and demonstrated a weight loss of up to 22.5% after 72 weeks of treatment. The data was published in the New England Journal of Medicine.